Systematic analysis of genetic vulnerabilities caused by chromosome loss events in cancer
- 1Stanford University School of Medicine, Stanford, California 94305, USA.
Abstract
Chromosome loss events are common across tumor types but rarely occur in normal tissue, raising the possibility that these alterations could be exploited as cancer-specific therapeutic vulnerabilities. Here, we integrate genome-scale CRISPR screening data with chromosome-level copy number profiles from 1,150 cancer cell lines and identify 389 dependencies that are selectively associated with individual chromosome loss events. The most significant vulnerabilities uncovered by our analysis are paralogous gene pairs, in which the loss of a paralog on an aneuploid chromosome establishes a unique dependency on its redundant paralog encoded elsewhere in the genome. We experimentally validate two paralog dependencies: loss of chromosome 8p, which encodes the phosphatase PPP2CB, creates a specific dependency on its paralog PPP2CA, while loss of the Y chromosome, which encodes the helicase DDX3Y, creates a specific dependency on its paralog DDX3X. Systematic benchmarking of CRISPR screening data indicates that the selective dependency on DDX3X in loss-of-Y cells exceeds other published aneuploidy-associated vulnerabilities and matches or exceeds most clinically-validated biomarker-target relationships. Furthermore, we found that the acute degradation of DDX3X was sufficient to trigger apoptosis in vitro and tumor regressions in mice. Collectively, these findings establish chromosome loss as a recurrent source of biomarker-defined therapeutic targets, identify paralog insufficiency as a general vulnerability in aneuploid cells, and provide in vivo proof-of-concept for targeting DDX3X in cancers with Y chromosome loss.
Related
- Management Strategies for Cutaneous Adverse Events Caused by Kinase Inhibitors in Oncology: A Systematic Review and Meta-Analysis
- Age-related clonal hematopoiesis and mosaic sex chromosome loss define distinct systemic proteomic programs and disease vulnerabilities
- Beyond illness severity: transdiagnostic cognitive vulnerabilities as independent predictors of psychological distress in parents of children with rare genetic disorders
- Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia
- Genetic and clinical phenotype analysis of a case of high-molecular-weight kininogen deficiency caused by a frameshift mutation c.628_629delAA in the KNG1 gene
BibTeX
@misc{bei2026systematic,
title = {{Systematic analysis of genetic vulnerabilities caused by chromosome loss events in cancer}},
author = {Y. Bei and J. Keane and M. Lynch and K. M. Tamaru and S. Lee and L. Qiao and P. K. Kandikuppa and G. Gauthier-Coles and W. Zhao and K. M. Schukken and I. Forrest and S. L. Thompson and S. Roessler and A. M. Taylor and J. M. Sheltzer},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.26.762060},
url = {https://www.biorxiv.org/content/10.64898/2026.10.26.762060v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Systematic analysis of genetic vulnerabilities caused by chromosome loss events in cancer
AU - Y. Bei
AU - J. Keane
AU - M. Lynch
AU - K. M. Tamaru
AU - S. Lee
AU - L. Qiao
AU - P. K. Kandikuppa
AU - G. Gauthier-Coles
AU - W. Zhao
AU - K. M. Schukken
AU - I. Forrest
AU - S. L. Thompson
AU - S. Roessler
AU - A. M. Taylor
AU - J. M. Sheltzer
PY - 2026
DA - 2026/10/26
PB - bioRxiv
DO - 10.64898/2026.10.26.762060
UR - https://www.biorxiv.org/content/10.64898/2026.10.26.762060v1
AB - Chromosome loss events are common across tumor types but rarely occur in normal tissue, raising the possibility that these alterations could be exploited as cancer-specific therapeutic vulnerabilities. Here, we integrate genome-scale CRISPR screening data with chromosome-level copy number profiles from 1,150 cancer cell lines and identify 389 dependencies that are selectively associated with individual chromosome loss events. The most significant vulnerabilities uncovered by our analysis are paralogous gene pairs, in which the loss of a paralog on an aneuploid chromosome establishes a unique dependency on its redundant paralog encoded elsewhere in the genome. We experimentally validate two paralog dependencies: loss of chromosome 8p, which encodes the phosphatase PPP2CB, creates a specific dependency on its paralog PPP2CA, while loss of the Y chromosome, which encodes the helicase DDX3Y, creates a specific dependency on its paralog DDX3X. Systematic benchmarking of CRISPR screening data indicates that the selective dependency on DDX3X in loss-of-Y cells exceeds other published aneuploidy-associated vulnerabilities and matches or exceeds most clinically-validated biomarker-target relationships. Furthermore, we found that the acute degradation of DDX3X was sufficient to trigger apoptosis in vitro and tumor regressions in mice. Collectively, these findings establish chromosome loss as a recurrent source of biomarker-defined therapeutic targets, identify paralog insufficiency as a general vulnerability in aneuploid cells, and provide in vivo proof-of-concept for targeting DDX3X in cancers with Y chromosome loss.
SN - 2692-8205
ER -